Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Operations: 2023-2025

Historic Cash from Operations for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$10.8 million.

  • Compass Therapeutics' Cash from Operations rose 1.83% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.1 million, marking a year-over-year increase of 6.24%. This contributed to the annual value of -$44.9 million for FY2024, which is 10.43% down from last year.
  • Per Compass Therapeutics' latest filing, its Cash from Operations stood at -$10.8 million for Q3 2025, which was up 8.31% from -$11.8 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Cash from Operations registered a high of -$5.9 million during Q3 2023, and its lowest value of -$13.9 million during Q1 2024.
  • Moreover, its 3-year median value for Cash from Operations was -$11.1 million (2024), whereas its average is -$11.0 million.
  • Within the past 5 years, the most significant YoY rise in Compass Therapeutics' Cash from Operations was 25.84% (2024), while the steepest drop was 86.61% (2024).
  • Quarterly analysis of 3 years shows Compass Therapeutics' Cash from Operations stood at -$12.4 million in 2023, then grew by 25.84% to -$9.2 million in 2024, then rose by 1.83% to -$10.8 million in 2025.
  • Its Cash from Operations stands at -$10.8 million for Q3 2025, versus -$11.8 million for Q2 2025 and -$13.2 million for Q1 2025.